Not all researchers reach the maximum dose
Findings Suggest Drug Has the Potential To Reduce the Risk of Heart Disease, Diabetes, and Stroke In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass, according to an industry-sponsored study presented virtually at ENDO 2021, the Endocrine Societys annual meeting
This ensures that each dose level gets evaluated with a consistent absorption profile
To date, there are no known undesirable effects caused by this amino acid-like substance, which goes on to collect long-chain fatty acids in the blood and conduct them to the mitochondria
Blood sugar levels do not rise as quickly after meals
They are concerned about uncontrolled release and unknown purity